# NIDA Clinical Trials Network: Big South/West Node

> **NIH NIH UG1** · UT SOUTHWESTERN MEDICAL CENTER · 2024 · $5,809,886

## Abstract

ABSTRACT
The Big South/West Node of the NIDA Clinical Trials Network (CTN) represents an expansion of the Texas
Node that has been a part of the CTN since 2005. With this expansion, the node will now be guided by the
shared leadership of Madhukar H. Trivedi, MD of University of Texas Southwestern Medical Center (UTSW)
Steven Shoptaw, PhD of UCLA, and Jennifer S. Potter, PhD, MPH, of UT Health Science Center at San
Antonio (UTHSCSA). This fourth competing renewal application builds on our successful track record of
leading CTN trials, being good network partners by providing excellent sites for multi-site studies, high
productivity in publishing, and training the next generation of scientists. During the 2015-2020 funding cycle,
our team developed and led: the largest pharmacotherapy trial for the treatment of methamphetamine use
disorder to date (extended-release naltrexone plus high-dose bupropion; CTN0068 ADAPT-2), an in-depth
study of the causes of death in a cohort of people living with HIV/HCV and substance use disorder
(CTN0064A1), and an implementation study to develop and deploy universal screening for opioid use disorder
and measurement based care using buprenorphine (CTN0090 MBC4OUD). Finally, a study testing transcranial
magnetic stimulation (TMS) as a treatment for stimulant use disorder has been approved for development, in
collaboration with the Southern Consortium Node (CTN0108). For this renewal application, we capitalize on the
experience of the Multiple PIs, who collectively have expertise in the treatment of stimulants, the treatment of
and public health response to the opioid crisis, and the treatment and care of HIV. Additional investigators
bring content expertise spanning addiction science and clinical care, translational science, dissemination and
implementation science, informatics, and trial implementation. The expanded Big South/West Node is named
to denote the importance of including geographic regions in the South that have historically not been
represented within the CTN (i.e., Arkansas, Oklahoma, Louisiana). This geographical expansion provides
greater access to diverse patient populations (e.g., diverse racial and ethnic groups; underinsured;
underserved; native [American Indian] and immigrant groups) within diverse settings (e.g., rural, urban). Our
existing partnerships with primary care networks, large health care systems, and use of electronic health
records (EHR) to positively impact substance use, has been further broadened to include multiple statewide
networks and resources in new partner states. Our research agenda includes a focus on the fourth wave of the
opioid epidemic, building upon the expertise of our investigators in treating stimulant and opioid use disorders,
and the changing needs of the regions we serve. Our team has experience with innovative study designs that
target all areas of the translational science continuum, and equip our Node to successfully and significantly
improve the care of pers...

## Key facts

- **NIH application ID:** 10799698
- **Project number:** 5UG1DA020024-20
- **Recipient organization:** UT SOUTHWESTERN MEDICAL CENTER
- **Principal Investigator:** Jennifer Sharpe Potter
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $5,809,886
- **Award type:** 5
- **Project period:** 2005-09-01 → 2025-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10799698

## Citation

> US National Institutes of Health, RePORTER application 10799698, NIDA Clinical Trials Network: Big South/West Node (5UG1DA020024-20). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10799698. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*